Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction - Test2 - elhamkhani - TriplyDB

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

http://www.wikidata.org/entity/Q28168881

about

Reappraisal of thienopyridine pretreatment in patients with non-ST elevation acute coronary syndrome: a systematic review and meta-analysis Personalized medicine: hope or hype?Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance Exploring predisposition and treatment response--the promise of genomics Antiplatelet therapy for carotid artery stenting Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Profile: An Update Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation?Polymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapy Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of actionin vitroandin vivo The role of antiplatelet therapy in the management of acute coronary syndromes Use of native or platelet count adjusted platelet rich plasma for platelet aggregation measurements Aspirin resistance: an evaluation of current evidence and measurement methods Antiplatelet therapy in ischemic stroke Therapeutic approaches in arterial thrombosis Determinants of the interindividual variability in response to antiplatelet drugs The variability of platelet response to aspirin and clopidogrel: revisiting the Caprie, Cure, Credo, and Match trials.Medications for the treatment of acute coronary syndromes Aspirin and clopidogrel resistance: an emerging clinical entity High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin Biological basis and clinical implications of acetylsalicylic acid resistance Suspected clopidogrel resistance in a patient with acute stent thrombosis Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes Response to aspirin and clopidogrel monitored with different platelet function methods Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'Aspirin and clopidogrel resistance: consideration and management Prasugrel Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel Oral antiplatelet therapy and percutaneous coronary intervention Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: perspectives from a large multinational registry Clopidogrel resistance: myth or reality?Stent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapy Optimizing platelet P2Y12 inhibition for patients undergoing PCI Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problems Antiplatelet therapy in populations at high risk of atherothrombosis Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study

P2860

Q22242057-6D54517A-A1EA-4A84-86D3-E1CAA819194F Q24289193-53F1623F-E621-4A6F-90CD-6B682F5910D2 Q26771106-DAA8D5EA-61B7-4C64-8665-A22C7AD6F5F2 Q26775125-C1A9D78A-4227-4FE1-A821-C9914D028B7E Q26824850-597A3AA5-1887-4D69-876A-E37B0C0AD8B2 Q26851609-26C43373-2405-4402-B391-5C605D9B0011 Q26852304-94CE694F-D616-4B85-B67B-64F8D99C98BA Q27006031-F8D34402-234A-4527-8616-810B3BFA6CC7 Q27022443-8A1DC0C6-3DDC-4609-B822-9E779B75C518 Q27022665-53B6D682-AAC9-4A76-B24E-CEDD635D0720 Q27649983-4B4B872C-6F53-4E48-81A1-666674B8E3D3 Q28176548-AB44D20B-98BA-4B2A-89E3-56F066EEC74C Q28181693-B19FF5D6-D3DE-459C-8A97-44920E561783 Q28183220-D017B7B4-02C1-4B28-90AF-C63119D59E04 Q28184366-465AACE6-026D-43E3-99A5-E822C7F3E0FE Q28187576-B20A88C2-677A-475E-9ADE-AF9AE07B205E Q28187591-359FE7F9-AE7B-467E-8481-2C4A1CD98F26 Q28192919-6AD678B3-F24D-496E-8024-2CFC25E5CA24 Q28193674-4DF6DBCC-65E0-4351-A992-1CFD62438A5B Q28194021-CE41BEFC-3D22-4416-BE05-0F8C5815FE90 Q28194081-B9456D60-F7D8-4B95-B452-07E765294AAB Q28195019-83CF4EA4-5BC0-4C55-9207-52AE3610E5AA Q28195139-66D6411D-87E4-47F6-8F50-EC9BC092FBDD Q28196159-71661A55-30CF-4B7E-875D-0CC44BC60020 Q28196661-471DDE3A-82DA-45C7-ABE4-253582A2AED6 Q28196714-F7986B1F-63CD-4174-8A54-CA1C8512EBB8 Q28199725-CF1CE3D9-65F9-4A48-965B-530B0F88A0D7 Q28200256-416E2C17-5AB2-4B14-B025-B0F3C4406D88 Q28200552-D30AF856-FC20-46A9-B5DE-AB11D9D9604D Q28200610-33A06E4F-0820-497D-A69E-39EC3E046800 Q28210429-816D983E-3EC7-4261-BEAB-F5D1971C51FA Q28214082-56F8AFB1-202A-4740-B313-5A4D324A1757 Q28217724-F3F7EDCD-F1EC-4A5D-A3AF-156AE4F4DDB7 Q28217870-72F802B7-E022-46F1-A519-393B813A8CBD Q28218055-B011CC6A-0F83-4D8C-ABD5-9125C11A2EA9 Q28218066-81820905-B9F5-4475-8568-44779ED28C4C Q28218094-F76CE54C-4A71-4C97-82DD-E2B81B25DE5E Q28218351-22F373D2-7027-43A7-9641-5B19DA3F31A2 Q28218702-FE743E24-BC8C-47C4-8680-E59EA0BEDCBE Q28218790-70E62E73-7678-427A-A635-136B12E3B4A3

P2860

Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction

http://www.wikidata.org/entity/Q28168881

description

2004 nî lūn-bûn

@nan

2004 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Clopidogrel resistance is asso ...... th acute myocardial infarction

@ast

Clopidogrel resistance is asso ...... th acute myocardial infarction

@en

Clopidogrel resistance is asso ...... th acute myocardial infarction

@nl

type

label

Clopidogrel resistance is asso ...... th acute myocardial infarction

@ast

Clopidogrel resistance is asso ...... th acute myocardial infarction

@en

Clopidogrel resistance is asso ...... th acute myocardial infarction

@nl

prefLabel

Clopidogrel resistance is asso ...... th acute myocardial infarction

@ast

Clopidogrel resistance is asso ...... th acute myocardial infarction

@en

Clopidogrel resistance is asso ...... th acute myocardial infarction

@nl

P1433

Q28168881-4728CE4B-0362-4E97-9414-D448F0481C00

P1476

Q28168881-34D24069-64DA-463F-87A5-3FC3C9E2CC2B

P2093

Q28168881-1A743229-2A1C-48B4-8F26-D3A2BBA3D147

Q28168881-4CD11899-F1D2-44DF-BBDD-BA9B780692CD

Q28168881-6789446F-D1C5-47CC-A181-44D66D223425

Q28168881-682488B6-A8C9-4DCF-A9CB-DCDE9F676152

Q28168881-72637753-8AA0-45C7-9A74-A314A1EDC9CD

Q28168881-75150D5F-8787-481D-A070-1E4F4E3B01D4

Q28168881-7A033BBF-73C6-4C02-933E-00A212E868B1

Q28168881-9A45228A-06C2-4BDE-968C-3E19E5C5FCEC

Q28168881-B93E254E-CB6A-4D6D-9A5D-A04C21D0C996

Q28168881-D0C8C99D-D2CD-46A0-B72C-0344463D7E73

P304

Q28168881-05EF55BF-A977-40FF-B99F-CEC76C885CCE

P31

Q28168881-B62C083A-0BF1-4484-B95A-B0A1BDB91FA9

P3181

Q28168881-43F31160-5673-4ACE-A2B6-FC5473D089B6

P356

Q28168881-CBEEFE22-A697-4035-B61A-9D8BACA27791

P407

Q28168881-F3ABCE24-760C-4A43-9F91-3404EF581C17

P433

Q28168881-09FF5B30-3567-4D05-A09C-D356CA286CE9

P478

Q28168881-9EAFCEDC-E2A9-4F01-A492-4DE7BF89FA72

P577

Q28168881-4C9324CD-76CC-4503-919F-6D5A50219CB0

P698

Q28168881-173C0A96-6EC6-49A7-80CD-25E77EDDD286

P921

Q28168881-1F059EAA-AFE3-4293-8AC7-FC92FEBC33E8

Q28168881-680D6F9E-FE41-4C32-A7C2-382B9C1D479C

P3181

P356

01.CIR.0000130846.46168.03

P1433

P1476

Clopidogrel resistance is asso ...... th acute myocardial infarction

@en

P2093

Boris Shenkman

http://www.w3.org/2001/XMLSchema#string

David Varon

http://www.w3.org/2001/XMLSchema#string

Hanna Pres

http://www.w3.org/2001/XMLSchema#string

Hanoch Hod

http://www.w3.org/2001/XMLSchema#string

Ilan Goldenberg

http://www.w3.org/2001/XMLSchema#string

Ilya Novikov

http://www.w3.org/2001/XMLSchema#string

Michael Shechter

http://www.w3.org/2001/XMLSchema#string

Naphtali Savion

http://www.w3.org/2001/XMLSchema#string

Roy Beinart

http://www.w3.org/2001/XMLSchema#string

Roy Bienart

http://www.w3.org/2001/XMLSchema#string

P304

3171-5

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1348394

http://www.w3.org/2001/XMLSchema#string

P356

10.1161/01.CIR.0000130846.46168.03

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P577

2004-06-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15184279

http://www.w3.org/2001/XMLSchema#string

P921